MARLBOROUGH, Mass., Nov. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023.
Dan Brennan, executive vice president and chief financial officer, and Lauren Tengler, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. A live webcast of the session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
CONTACTS:
Media:
Katie Schur
508-683-5574 (office)
Media Relations
Boston Scientific Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Lauren Tengler
508-683-4479 (office)
Investor Relations
Boston Scientific Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$103.83 |
| Daily Change: | -0.49 -0.47 |
| Daily Volume: | 5,490,169 |
| Market Cap: | US$153.670B |
July 07, 2025 April 23, 2025 March 03, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
